Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Heinemann

Obstetrics & Gynecology Summerville, SC Medical Doctor

NPI 1609939990 CMS profile 27959

83 Springview Ln, Summerville, SC 29485

Open in the dashboard

General payments

$7,028

395 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$4

4 holdings reported · through program year 2025

Through program year 2025, Jennifer Heinemann of Summerville, SC is reported in the CMS Open Payments database as having received $7,028 across 395 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $4 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,107 59
2024 General $1,404 70
2023 General $1,468 84
2022 General $1,451 82
2021 General $764 47
2020 General $432 28
2019 General $402 25
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Heinemann
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Jennifer Heinemann were reported at $1,107. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Jennifer Heinemann Obstetrics & Gynecology median Middle half National median
2019 $402 $172 $62–$391 $163
2020 $432 $94 $36–$222 $114
2021 $764 $136 $42–$369 $132
2022 $1,451 $160 $50–$433 $149
2023 $1,468 $169 $56–$423 $160
2024 $1,404 $152 $50–$371 $164
2025 $1,107 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,645 107 payments
  2. Sumitomo Pharma America, Inc. $1,073 44 payments
  3. Mayne Pharma Inc. $590 39 payments
  4. Hologic, LLC $423 17 payments
  5. Shield Therapeutics Inc $368 19 payments
  6. Exeltis, USA Inc. $288 17 payments
  7. Organon LLC $270 19 payments
  8. Astellas Pharma US Inc $218 11 payments
  9. Myovant Sciences Inc. $207 14 payments
  10. TherapeuticsMD, Inc. $196 13 payments
  11. Other $1,749 95 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,987 392 payments
  2. Education $41 3 payments
Products named General payments · program years 2019–2025
  1. MYFEMBREE Hormone Therapy $1,014 52 payments
  2. LO LOESTRIN FE $970 66 payments
  3. ORILISSA $933 64 payments
  4. ORIAHNN $626 39 payments
  5. ACCRUFER $368 19 payments
  6. LILETTA $290 17 payments
  7. MYFEMBREE Womens Health $266 6 payments
  8. Aptima $257 9 payments
  9. NEXPLANON $240 17 payments
  10. THINPREP 2000 PROCESSOR $223 7 payments
  11. Other $3,474 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

171

Median for Obstetrics & Gynecology: 65

Drug cost

$8,730

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

44.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Osphena Ospemifene Brand 12 $4,316
Estradiol Generic 72 $2,169
Valacyclovir Valacyclovir Hcl Brand 22 $1,238
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 28 $680
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 14 $241
Fluconazole Generic 23 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$16,869

Medicare's payments for the services billed

Medicare patients

76

Average age 69

Services billed

834

76 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 38%
Diabetes 22%
Osteoporosis 22%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $390
$390 — —
SLYND
  • Exeltis, USA Inc. $90
$90 — —
Veozah
  • Astellas Pharma US Inc $68
$68 — —
FEMRING
  • MILLICENT US INC $27
$27 — —
INTRAROSA
  • MILLICENT US INC $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record